Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 1, pp 126–132 | Cite as

Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients

  • Raquel Olmos-Jiménez
  • María Sacramento Díaz-Carrasco
  • Ana Galera-Miñarro
  • Juan Francisco Pascual-Gazquez
  • Alberto Espuny-Miró
Research Article

Abstract

Background The administration of triple intrathecal therapy with methotrexate, cytarabine and a corticosteroid for the prophylaxis and treatment of neoplastic cell infiltration in the central nervous system in hematological malignancies is a widespread practice. There is limited information available about its toxicity profile. Several factors related to intrathecal preparation can affect toxicity. Thus, it was decided to standardize intrathecal chemotherapy, trying to obtain the best toxicity profile. Objective To assess the toxicity of a standardized triple intrathecal chemotherapy in oncohematological pediatric patients and to establish risk factors of toxicity. Setting Oncohematological pediatric unit from a tertiary hospital in Spain. Methods Prospective, descriptive and observational study in which all the administrations of standardized triple intrathecal chemotherapy in pediatric patients were registered. Main outcome measure Toxicity of the intrathecal therapy was recorded and possible risk factors were assessed. Results A total of 269 administrations of triple intrathecal chemotherapy were registered in 41 patients (mean age = 6.6 ± 3.9 years). In 16.7% of the procedures, an adverse event was reported (total number of adverse events = 61). 47.5% were grade 1, 47.5% grade 2 and 4.9% grade 3. The administration of intrathecal chemotherapy inpatient and patient age ≥3 years were risk factors of toxicity in the multivariate analysis. Conclusions The administration of standardized triple intrathecal chemotherapy is related to a low frequency of toxicity and most of the adverse events registered were mild/moderate. The detection of adverse effects was significantly greater in children with age greater than or equal to three years and in hospitalized patients.

Keywords

Drug toxicity Factors Hematological neoplasms Intrathecal chemotherapy Pediatrics Risk Spain Standardization 

Notes

Funding

This study had no special source of funding.

Conflicts of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11:871–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Franklin JL, Finlay J. Leukemias and lymphomas: treatment and prophylaxis of the central nervous system. Curr Treat Options Neurol. 2006;8:335–45.CrossRefPubMedGoogle Scholar
  3. 3.
    Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group. Blood. 2006;108:1165–73.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bleyer WA, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983;1:317–25.PubMedGoogle Scholar
  5. 5.
    Sullivan MP, Moon TE, Trueworthy R, Vietti TJ, Humphrey GB, Komp D. Combination intrathecal therapy for meningeal leukemia: two versus three drugs. Blood. 1977;50:471–9.PubMedGoogle Scholar
  6. 6.
    Lin WY, Liu HC, Yeh TC, Wang LY, Liang DC. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:523–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Nagpal S, Recht L. Treatment and prophylaxis of hematologic malignancy in the central nervous system. Curr Treat Options Neurol. 2011;13:400–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Vagace JM, de la Maya MD, Caceres-Marzal C, de Gonzalez MS, Gervasini G. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma. Crit Rev Oncol Hematol. 2012;84:274–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Cradock JC, Kleinman LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm. 1978;35:402–6.PubMedGoogle Scholar
  10. 10.
    de Lemos ML, Monfared S, Denyssevych T, Hamata L, Jennings S, Thiessen B, et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer’s solution for intrathecal administration. J Oncol Pharm Pract. 2009;15:45–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Gil Lujan G, Clemente Bautista S, Oliveras Arenas M, Cabañas Poy MJ, Hidalgo Albert E. Dosage of drugs for cerebrospinal administration. Farm Hosp. 2005;29:185–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Pui CH; American Society of Hematology. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology. 2006;1:142–6.Google Scholar
  13. 13.
    American Society of Health-System Pharmacists. AHFS drug information. Bethesda: American Society of Health-System Pharmacists (ASHP) Inc; 2008. ISBN 978-1-58528-206-7.Google Scholar
  14. 14.
    Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMAALL-89 TRIAL. Haematologica. 2001;86:586–95.PubMedGoogle Scholar
  15. 15.
    Olmos-Jiménez R, Espuny-Miró A, Díaz-Carrasco MS, Fernández-Varón E, Valderrey-Pulido M, Cárceles-Rodríguez C. Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use. J Oncol Pharm Pract. 2016;22:659–65.CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Giebel S, Krawczyk-Kulis M, Mczyk-Cioch M, Czyz A, Lech-Maranda E, Piatkowska-Jakubas B, et al. Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn. 2008;118:356–61.PubMedGoogle Scholar
  18. 18.
    Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Cancer Institute 2013 [cited 2016 Sep 11]. http://www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf.
  19. 19.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMedGoogle Scholar
  20. 20.
    Magge RS, De Angelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Evans RW. Complications of lumbar puncture. Neurol Clin. 1998;16:83–105.CrossRefPubMedGoogle Scholar
  22. 22.
    Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–59.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712–22.PubMedGoogle Scholar
  24. 24.
    Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45:189–95.PubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Raquel Olmos-Jiménez
    • 1
  • María Sacramento Díaz-Carrasco
    • 2
  • Ana Galera-Miñarro
    • 3
  • Juan Francisco Pascual-Gazquez
    • 3
  • Alberto Espuny-Miró
    • 1
  1. 1.Pharmacology Department, Faculty of MedicineUniversity of MurciaMurciaSpain
  2. 2.Pharmacy ServiceVirgen de la Arrixaca Clinical University HospitalMurciaSpain
  3. 3.Pediatric Oncohematology Department, Pediatric ServiceVirgen de la Arrixaca Clinical University HospitalMurciaSpain

Personalised recommendations